Table 2.
In vitro anti-HIV data of compounds 1–8 a.
| Compound | EC50 (μg/mL) NL4-3 b | CC50 (μg/mL) MT4 c | TI e |
|---|---|---|---|
| 1 | 2.4 ± 0.53 | 17 ± 2.5 | 7.1 |
| 2 | *- d 3.7 ± 1.9 | 15.2 ± 3.1 | |
| 3 | *- d | ||
| 4 | *- d | ||
| 5 | *- d | ||
| 6 | *- d | ||
| 7 | >25 | >25 | |
| 8 | *- d | ||
| AZT f | 0.0055 ± 0.0018 | >0.1 | 18.2 |
a The highest concentrations for the tested compounds and AZT were 25 μg/mL and 0.1 μg/mL, respectively. Testing was done with a series of 4-fold dilutions (six concentrations). b EC50: 50% HIV-inhibitory concentration (mean ± SD of 3 tests). c CC50: 50% cytotoxic concentration. d *-: no selective anti-HIV activity (CC50/EC50 < 5). e TI: CC50/EC50. f AZT: azidothymidine.